Bottom line: Prophylaxis with trimethoprim-sulfamethoxazole (TMP-SMX) appears to be effective in immunocompromised patients without HIV infection.
Systematic review of 11 RCTs or quasi-RCTs including (1155 patients) between 1974 and 1997 comparing TMP-SMX to placebo or to fluoroquinolones. Only a few of the trials included descriptions of randomization and allocation concealment procedures.
RESULTS: Forest plot in Analysis 1.1 shows that compared to placebo or to other treatment, TMP-SMX provides statistically significant benefit (
How I found it: DynaMed (PCP article)